2025
2855 Dementia in elderly individuals with depression: a systematic review and Meta-analysis of longitudinal studies (2013–2024)
da Costa Galvão P, de Sousa Romeiro A, de Souza G, Prudente T, Dias E, Nogueira T, Silveira E. 2855 Dementia in elderly individuals with depression: a systematic review and Meta-analysis of longitudinal studies (2013–2024). Age And Ageing 2025, 54: afae277.130. DOI: 10.1093/ageing/afae277.130.Peer-Reviewed Original ResearchMild cognitive impairmentOlder adultsMeta-analysis of longitudinal studiesMeta-analysisLikelihood of older adultsSystematic reviewMini-Mental State ExaminationGeriatric Depression ScaleAssociated with higher likelihoodSymptoms of mild cognitive impairmentDepressed older adultsIdentification of risk factorsConclusion DepressionNon-depressed populationDepression ScaleMini-MentalState ExaminationDepressive symptomsTargeted interventionsI2 statisticAssess symptomsPRISMA recommendationsCohort studyDementiaStudy heterogeneity
2021
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
Domingo P, Mur I, Mateo G, Gutierrez M, Pomar V, de Benito N, Corbacho N, Herrera S, Millan L, Muñoz J, Malouf J, Molas M, Asensi V, Horcajada J, Estrada V, Gutierrez F, Torres F, Perez-Molina J, Fortun J, Villar L, Hohenthal U, Marttila H, Vuorinen T, Nordberg M, Valtonen M, Frigault M, Mansour M, Patel N, Fernandes A, Harvey L, Foulkes A, Healy B, Shah R, Bensaci A, Woolley A, Nikiforow S, Lin N, Sagar M, Shrager H, Huckins D, Axelrod M, Pincus M, Fleisher J, Lampa J, Nowak P, Vesterbacka J, Rasmuson J, Skorup P, Janols H, Niward K, Chatzidionysiou K, Asgeirsson H, Parke Å, Blennow O, Svensson A, Aleman S, Sönnerborg A, Henter J, Horne A, Al-Beidh F, Angus D, Annane D, Arabi Y, Beane A, Berry S, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Cheng A, Cove M, De Jong M, Derde L, Estcourt L, Goossens H, Gordon A, Green C, Haniffa R, Ichihara N, Lamontagne F, Lawler P, Litton E, Marshall J, McArthur C, McAuley D, McGuinness S, McVerry B, Montgommery S, Mouncey P, Murthy S, Nichol A, Parke R, Parker J, Reyes F, Rowan K, Saito H, Santos M, Seymour C, Shankar-Hari M, Turgeon A, Turner A, van Bentum-Puijk W, van de Veerdonk F, Webb S, Zarychanski R, Baillie J, Beasley R, Cooper N, Fowler R, Galea J, Hills T, King A, Morpeth S, Netea M, Ogungbenro K, Pettila V, Tong S, Uyeki T, Youngstein T, Higgins A, Lorenzi E, Berry L, Salama C, Rosas I, Ruiz-Antorán B, Muñez Rubio E, Ramos Martínez A, Campos Esteban J, Avendaño Solá C, Pizov R, Sanz Sanz J, Abad-Santos F, Bautista-Hernández A, García-Fraile L, Barrios A, Gutiérrez Liarte Á, Alonso Pérez T, Rodríguez-García S, Mejía-Abril G, Prieto J, Leon R, VEIGA V, SCHEINBERG P, FARIAS D, PRATS J, CAVALCANTI A, MACHADO F, ROSA R, BERWANGER O, AZEVEDO L, LOPES R, DOURADO L, CASTRO C, ZAMPIERI F, AVEZUM A, LISBOA T, ROJAS S, COELHO J, LEITE R, CARVALHO J, ANDRADE L, SANDES A, PINTÃO M, SANTOS S, ALMEIDA T, COSTA A, GEBARA O, FREITAS F, PACHECO E, MACHADO D, MARTIN J, CONCEIÇÃO F, SIQUEIRA S, DAMIANI L, ISHIHARA L, SCHNEIDER D, DE SOUZA D, Hermine O, Mariette X, Tharaux P, Resche Rigon M, Porcher R, Ravaud P, Azoulay E, Cadranel J, Emmerich J, Fartoukh M, Guidet B, Humbert M, Lacombe K, Mahevas M, Pene F, Pourchet-Martinez V, Schlemmer F, Tibi A, Yazdanpanah Y, Dougados M, Bureau S, Horby P, Landray M, Baillie K, Buch M, Chappell L, Day J, Faust S, Haynes R, Jaki T, Jeffery K, Juszczak E, Lim W, Mafham M, Montgomery A, Mumford A, Thwaites G, Kamarulzaman A, Syed Omar S, Ponnampalavanar S, Raja Azwa R, Wong P, Kukreja A, Ong H, Sulaiman H, Basri S, Ng R, Megat Johari B, Rajasuriar R, Chong M, Neelamegam M, Syed Mansor S, Zulhaimi N, Lee C, Altice F, Price C, Malinis M, Hasan M, Wong C, Chidambaram S, Misnan N, Mohd Thabit A, Sim B, Bidin F, Mohd Abd Rahim M, Saravanamuttu S, Tuang W, Mohamed Gani Y, Thangavelu S, Tay K, Ibrahim N, Halid L, Tan K, Mukri M, Arip M, Koh H, Syed Badaruddin S, Raja Sureja L, Chun G, TORRE-CISNEROS J, MERCHANTE N, LEON R, CARCEL S, GARRIDO J, Galun E, Soriano A, Martínez J, Castán C, Paredes R, Dalmau D, Carbonell C, Espinosa G, Castro P, Muñóz J, Almuedo A, Prieto S, Pacheco I, Ratain M, Pisano J, Strek M, Adegunsoye A, Karrison T, Jozefien D, Karel F.A. V, Elisabeth D, Cedric B, Bastiaan M, Shankar-Hari M, Vale C, Godolphin P, Fisher D, Higgins J, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty J, Berry L, Broman N, Cavalcanti A, Colman R, De Buyser S, Derde L, Domingo P, Omar S, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon A, Haynes R, Hermine O, Horby P, Horick N, Kumar K, Lambrecht B, Landray M, Leal L, Lederer D, Lorenzi E, Mariette X, Merchante N, Misnan N, Mohan S, Nivens M, Oksi J, Perez-Molina J, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan A, Ravaud P, Reid P, Rutgers A, Sancho-Lopez A, Seto T, Sivapalasingam S, Soin A, Staplin N, Stone J, Strohbehn G, Sunden-Cullberg J, Torre-Cisneros J, Tsai L, van Hoogstraten H, van Meerten T, Veiga V, Westerweel P, Murthy S, Diaz J, Marshall J, Sterne J. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA 2021, 326: 499-518. PMID: 34228774, PMCID: PMC8261689, DOI: 10.1001/jama.2021.11330.Peer-Reviewed Original ResearchConceptsIL-6 antagonistsUsual careCause mortalitySummary odds ratiosOdds ratioEligible trialsMechanical ventilationClinical trialsMortality riskSecondary infectionCOVID-19Primary outcome measureAbsolute mortality riskBias assessment toolRisk of biasStudy selection criteriaCochrane riskSecondary outcomesI2 statisticPlaceboOutcome measuresMAIN OUTCOMEPatientsAdditional trialsPrimary analysis
2020
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors
Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Dimopoulos MA, Facon T, Usmani SZ, Mateos MV, Costa LJ. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors. JAMA Oncology 2020, 6: 1759-1765. PMID: 32970151, PMCID: PMC7516804, DOI: 10.1001/jamaoncol.2020.4338.Peer-Reviewed Original ResearchConceptsProgression-free survivalHigh-risk MMBackbone regimensRefractory MMHazard ratioMultiple myelomaClinical trialsSystematic reviewDerSimonian-Laird random-effects modelPhase 3 trialImproved response ratesPreferred Reporting ItemsRandom-effects modelCochrane riskSame regimenCytogenetic riskCochrane LibraryMeeting libraryI2 statisticImproved outcomesMAIN OUTCOMEThird investigatorCochran's QPatientsReporting ItemsPharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis
Deng J, Silver Z, Huang E, Zheng E, Kavanagh K, Wen A, Cheng W, Dobransky J, Sanger S, Grammatopoulos G. Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis. Rheumatology 2020, 60: 649-657. PMID: 32572480, DOI: 10.1093/rheumatology/keaa228.Peer-Reviewed Original ResearchConceptsNon-vertebral fracturesDecreased oddsAdult patientsSystematic reviewNon-vertebral fracture incidenceAnti-fracture efficacyCochrane Central RegisterSystematic review registrationVitamin D metabolitesAllied Health LiteratureInternational Prospective RegisterWeb of ScienceGlucocorticoid therapyEligible patientsCentral RegisterControlled TrialsPharmacological preventionVertebral fracturesFracture incidenceReview registrationGC therapyVitamin D.D metabolitesProspective RegisterI2 statistic
2019
Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials
Holleck JL, Merchant N, Gunderson CG. Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal Of General Internal Medicine 2019, 34: 1018-1024. PMID: 30937668, PMCID: PMC6544709, DOI: 10.1007/s11606-019-04899-7.Peer-Reviewed Original ResearchConceptsSymptom-triggered therapyDuration of therapyAlcohol withdrawal syndromeBenzodiazepine doseWithdrawal syndromeTrial of patientsLow-risk patientsGeneral hospital settingRandomized Controlled TrialsRisk of biasTerms of mortalitySystematic literature searchStrength of evidenceBenzodiazepine dosageDose therapyMedication classesCochrane RegistryCochrane riskDose regimensAlcohol withdrawalBias toolControlled TrialsDose scheduleResultsSix studiesI2 statistic
2018
Do Patients with Cellulitis Need to be Hospitalized? A Systematic Review and Meta-analysis of Mortality Rates of Inpatients with Cellulitis
Gunderson CG, Cherry BM, Fisher A. Do Patients with Cellulitis Need to be Hospitalized? A Systematic Review and Meta-analysis of Mortality Rates of Inpatients with Cellulitis. Journal Of General Internal Medicine 2018, 33: 1553-1560. PMID: 30022408, PMCID: PMC6108983, DOI: 10.1007/s11606-018-4546-z.Peer-Reviewed Original ResearchConceptsInfectious Diseases SocietyOutpatient managementMortality rateDiseases SocietyNewcastle-Ottawa Quality Assessment ScaleActual clinical evidencePneumonia severity indexCommunity-acquired pneumoniaLow-risk patientsQuality Assessment ScaleThird of deathsWorldwide mortality rateRandom-effects modelSystematic literature searchInpatient mortalityRisk patientsConsecutive patientsClinical evidenceResultsEighteen studiesDiseases codesI2 statisticCommon causeInclusion criteriaStudy qualityCellulitis
2014
Effectiveness and Safety of Patient Activation Interventions for Adults with Type 2 Diabetes: Systematic Review, Meta-Analysis, and Meta-regression
Bolen SD, Chandar A, Falck-Ytter C, Tyler C, Perzynski AT, Gertz AM, Sage P, Lewis S, Cobabe M, Ye Y, Menegay M, Windish DM. Effectiveness and Safety of Patient Activation Interventions for Adults with Type 2 Diabetes: Systematic Review, Meta-Analysis, and Meta-regression. Journal Of General Internal Medicine 2014, 29: 1166-1176. PMID: 24733301, PMCID: PMC4099447, DOI: 10.1007/s11606-014-2855-4.Peer-Reviewed Original ResearchConceptsWeighted mean differenceShort-term mortalityRandom-effects modelOdds ratioActivation interventionUsual care/control groupsIntermediate outcomesHigher baseline A1CPatient activation interventionPharmacist-led interventionsLong-term mortalityLong-term outcomesPooled odds ratioType 2 diabetesIntervention strategiesBaseline outcome valuesUncontrolled glycemiaBaseline A1CCause mortalityGlycemic controlMethodsElectronic databasesRandomized trialsPrimary careI2 statisticStatistical heterogeneity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply